about
Reduced-fat foods: the complex science of developing diet-based strategies for tackling overweight and obesityPharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsPolymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs.A simple quantitative approach for the determination of long and medium chain lipids in bio-relevant matrices by high performance liquid chromatography with refractive index detection.Critical concentrations in the dilution of oral self-microemulsifying drug delivery systems.Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization.Effect of lipolysis on drug release from self-microemulsifying drug delivery systems (SMEDDS) with different core/shell drug location.Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems.Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.Preparation and evaluation of poly(ethylene glycol)-poly(lactide) micelles as nanocarriers for oral delivery of cyclosporine a.Nanoparticles based on hydrophobic alginate derivative as nutraceutical delivery vehicle: vitamin D3 loading.Self-microemulsifying drug delivery systems (SMEDDS) for improving in vitro dissolution and oral absorption of Pueraria lobata isoflavone.Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigationClinical studies with oral lipid based formulations of poorly soluble compoundsEffect of ingested lipids on drug dissolution and release with concurrent digestion: a modeling approach.In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design.Lipid-Based Drug Delivery Systems.Development and Evaluation of Novel Self-Nanoemulsifying Drug Delivery Systems Based on a Homolipid from Capra hircus and Its Admixtures with Melon Oil for the Delivery of IndomethacinCharacterising lipid lipolysis and its implication in lipid-based formulation development.Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs.Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery?Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.Preparation and evaluation of self-nanoemulsifying tablets of carvedilol.Controlling lipid bioavailability through physicochemical and structural approaches.Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids.Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals.Development of food-grade nanoemulsions and emulsions for delivery of omega-3 fatty acids: opportunities and obstacles in the food industry.Self-assembled structures formed during lipid digestion: characterization and implications for oral lipid-based drug delivery systems.Standardization of Nanoparticle Characterization: Methods for Testing Properties, Stability, and Functionality of Edible Nanoparticles.Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model.Encapsulation and Delivery of Crystalline Hydrophobic Nutraceuticals using Nanoemulsions: Factors Affecting Polymethoxyflavone Solubility.Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.Novel lipid-free nanoformulation for improving oral bioavailability of coenzyme Q10.The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.Effect of formulation variables on preparation and evaluation of gelled self-emulsifying drug delivery system (SEDDS) of ketoprofen.
P2860
Q27003112-5D188F6C-1BA5-4476-BEF2-478996E61B2AQ28084784-B367FCFE-1407-495A-9660-DA68999B4305Q30451024-16F1E152-B6B5-4636-BB7D-A1CF384E08A9Q30543782-6B38D6C7-E094-4BD1-B838-366CE105DD3EQ33514056-BD3215D0-098D-40C2-AF53-E017B6AAE3F8Q33633359-B71DD1E7-E6C8-4D0E-BFB2-3D69DCA7D276Q33681221-111C6BC7-33C9-428D-8F03-C7D6AD348D20Q33710442-AD5518CC-D5C3-4431-A295-E36E78CA0706Q33893117-16A49376-FA16-4C28-897F-E22A3E0C6DCDQ33947896-0DBAF140-D537-4F81-8963-413F8C581CFBQ33977471-4F267F5A-1AE5-4AA3-A1D6-7F17ED697B4BQ34441945-0E53C373-7BEE-4B16-BA3F-EE959CE95A37Q34562249-30D55F09-571F-4237-9A8B-0A2A83EAE96DQ34610539-DCA97153-C542-4696-9D78-60D1C4C3AE62Q34778043-59B5A2F9-EA69-42F6-A112-40D570F2A841Q34799545-CF67C441-7D79-4D8D-8AB5-DACF4F86327AQ35488199-D070F3F5-3E43-4BD6-9E78-3A0CA48AD601Q35717232-A3D42CD8-BB97-4540-B245-3BB370374997Q36112195-41874C15-8275-4A42-9EEB-D515364A897AQ36112240-2B95771A-00C0-4D37-836A-EC09B82A357BQ36331543-0C0E5EC7-3B59-4437-BFEA-56662E953AB5Q36349701-C2F47B99-0121-48B4-B48A-C0CF057E1F77Q36585620-E1B00C7D-E666-40D6-9517-12C8E01ED278Q36748145-677191A6-1A4F-49E8-A361-3DA7089A6755Q36909311-47BD2C3D-1DF4-4696-B519-96A16628F45CQ37146180-A8EB5CFC-4DF3-403D-9247-FF4368247134Q37307707-79322EB1-B145-416C-8A55-DC513BC3FB5AQ37702234-72594B5B-286D-4C1D-8B3B-45CB8C37048CQ37967163-EF08A813-6181-4EB0-A687-6FB8FA83C6B8Q37988960-BCCEB83D-D7EE-4C08-B40D-EDAB56DAF427Q38242752-7B2FF867-EC2D-4EB4-868B-0D8C983E3A20Q38266724-9CECDF7E-7979-409D-B2DE-92CFD1744390Q38383061-1863016B-2087-4645-B837-EB358445B2C7Q38409560-115EB01D-1E3A-401F-B24F-9C7C7B33843AQ38970984-F5411531-FE46-49F1-B011-44091CBCE5B9Q40261316-8134AFEF-5C75-4E9E-B12F-B26F5A465AB9Q40594909-DF9AC524-2208-417F-A8E0-81FB19CEB7F8Q41060608-CA3049BA-7833-496B-8B73-F05A2E0AA4D9Q41889403-248EAE1E-0BBB-425A-8822-E7559C06DAFDQ41990361-9C5DC260-4130-429D-9537-757F2C7AA68A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro assessment of oral lipid based formulations.
@ast
In vitro assessment of oral lipid based formulations.
@en
In vitro assessment of oral lipid based formulations.
@nl
type
label
In vitro assessment of oral lipid based formulations.
@ast
In vitro assessment of oral lipid based formulations.
@en
In vitro assessment of oral lipid based formulations.
@nl
prefLabel
In vitro assessment of oral lipid based formulations.
@ast
In vitro assessment of oral lipid based formulations.
@en
In vitro assessment of oral lipid based formulations.
@nl
P1476
In vitro assessment of oral lipid based formulations.
@en
P2093
P304
P356
10.1016/S0169-409X(01)00182-X
P407
P478
50 Suppl 1
P577
2001-10-01T00:00:00Z